CLDX

Celldex Therapeutics Inc

34.54

Sep 22 • 3:00 PM ET -3.35 (-8.83%)

Healthcare Biotechnology USA Mid NASD

Today, 1:20 PMCelldex barzolvolimab meets primary and all key secondary endpoints in two Phase 3 chronic spontaneous urticaria trials

Peers: TNGX CGON KYMR AXSM BMRN CRNX INCY RYTM APGE KRYS

| Held by: VTI IWM XBI VXF IWO VTWO SCHA VHT DFAS DFMC

Scroll to Statements

Index	RUT
Market Cap	2.71B
Enterprise Value	2.01B
Income	-300.55M
Sales	0.16M
Book/sh	9.10
Cash/sh	9.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	198
IPO	May 15, 1986

P/E	-
Forward P/E	-
PEG	-
P/S	16954.99
P/B	3.80
P/C	3.81
P/FCF	-
EV/EBITDA	-
EV/Sales	12540.06
Quick Ratio	11.82
Current Ratio	11.82
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-4.36
EPS next Y	-4.21
EPS next Q	-1.02
EPS this Y	-6.78%
EPS next Y	-1.10%
EPS next 5Y	4.11%
EPS past 3/5Y	-17.59% -14.07%
Sales past 3/5Y	-13.13% -26.93%
EPS Y/Y TTM	-44.90%
Sales Y/Y TTM	-97.27%
EPS Q/Q	-10.77%
Sales Q/Q	-96.99%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	11.03% -97.01%

Insider Own	3.32%
Insider Trans	0.00%
Inst Own	106.05%
Inst Trans	19.58%
ROA	-40.76%
ROE	-43.88%
ROIC	-41.86%
Gross Margin	-2049.37%
Oper. Margin	-206220.25%
Profit Margin	-190220.89%
SMA20	-11.16%
SMA50	-11.46%
SMA200	7.24%
Trades

Shs Outstand	78.50M
Shs Float	75.92M
Short Float	11.38%
Short Ratio	8.63
Short Interest	8.64M
52W High	45.14 -23.47%
52W Low	22.10 56.31%
Volatility	5.09% 3.86%
ATR (14)	2.15
RSI (14)	30.78
Beta	0.87
Rel Volume	12.27
Avg Volume	1.00M
Volume	10,492,084

Perf Week	-10.30%
Perf Month	-14.45%
Perf Quarter	4.75%
Perf Half Y	8.63%
Perf YTD	27.19%
Perf Year	38.96%
Perf 3Y	35.74%
Perf 5Y	-36.37%
Perf 10Y	-38.09%
Recom	1.20
Target Price	61.43
Prev Close	37.89
Price	34.54
Change %	-8.83%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Reiterated	H.C. Wainwright	Buy	$42 → $64
Apr-20-26	Upgrade	Barclays	Underweight → Overweight	$45
Mar-23-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$44
Oct-21-25	Initiated	Mizuho	Outperform	$48
Oct-13-25	Initiated	Barclays	Underweight	$25
Apr-28-25	Initiated	Canaccord Genuity	Buy	$64
Mar-20-25	Initiated	Morgan Stanley	Overweight	$46
Feb-13-25	Initiated	UBS	Buy	$44
Oct-07-24	Initiated	Citigroup	Buy	$70
Sep-30-24	Initiated	Goldman	Neutral	$45
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy	$58
Jun-11-24	Initiated	Wolfe Research	Outperform	$51
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$27
Aug-22-23	Initiated	Wells Fargo	Underweight	$21
Sep-17-21	Initiated	Jefferies	Buy	$66
Sep-10-21	Initiated	SVB Leerink	Outperform	$68
Jul-22-21	Initiated	Guggenheim	Buy	$66
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight	$8

Show Previous Ratings

Today 01:10PM	CLDX Stock Slumps 11% This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns Misplaced (Stocktwits) -8.83%
09:40AM	Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials (InvestorsHub)
06:58AM	Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints (GlobeNewswire)
Sep-08-26 04:01PM	Celldex to Present at Upcoming Investor Conference (GlobeNewswire)
Aug-06-26 04:48PM	Celldex: Q2 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Celldex Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-26 05:33AM	Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study (BioPharma Dive)
Jul-21-26 06:52PM	CLDX Stock Down 10% After-Hours Whats Driving The Selloff? (Stocktwits)
04:01PM	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis (GlobeNewswire)
Jul-15-26 04:01PM	Celldex Announces Planned Transition of Chief Financial Officer (GlobeNewswire) -7.60%
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
Jun-14-26 10:21AM	Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting (GlobeNewswire)
05:15AM	Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting (GlobeNewswire)
Jun-10-26 04:01PM	Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress (GlobeNewswire)
May-07-26 04:37PM	Celldex: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Celldex Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-13-26 04:01PM	Celldex to Present at Upcoming Investor Conference (GlobeNewswire)
Apr-06-26 10:53AM	Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-02-26 12:26PM	Celldex shares plunge after dumping $300 million stock deal (GuruFocus.com)
Apr-01-26 09:48PM	Celldex Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire)
04:01PM	Celldex Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-26 10:30AM	Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 (GlobeNewswire)
Mar-08-26 11:46AM	Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference (MarketBeat)
Mar-01-26 09:45AM	Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 (GlobeNewswire)
Feb-28-26 01:26PM	Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory (Insider Monkey)
Feb-27-26 02:45PM	Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 (GlobeNewswire)
Feb-26-26 01:52PM	Celldex Therapeutics Stock Earns 88 RS Rating (Investor's Business Daily)
Feb-25-26 04:37PM	Celldex: Q4 Earnings Snapshot (Associated Press Finance) +24.07%
04:01PM	Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
07:01AM	Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria (GlobeNewswire)
08:01AM	Loading…
Feb-23-26 08:01AM	Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile (GlobeNewswire) +5.65%
Feb-12-26 01:38AM	Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit (MarketBeat)
Feb-11-26 12:01AM	Top Picks 2026- Celldex Therapeutics Inc. CLDX (MoneyShow)
Feb-09-26 08:01AM	Celldex to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-27-26 04:02PM	2 Strong Buy Growth Stocks With Upside of Around 200% (Barchart) -5.57%
Dec-22-25 03:46PM	Celldex Therapeutics Stock Gets RS Rating Lift (Investor's Business Daily) +6.52%
Dec-21-25 09:57AM	Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 (Insider Monkey)
Dec-09-25 08:01AM	Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism (GlobeNewswire) -5.74%
Nov-10-25 04:34PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance) +7.50%
04:01PM	Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:01AM	Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer (GlobeNewswire)
Nov-07-25 08:01AM	Celldex to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-25 08:00AM	Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 (GlobeNewswire)
08:00AM	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study (GlobeNewswire)
Oct-30-25 04:01PM	Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition (GlobeNewswire)
Oct-20-25 11:08PM	Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating (Insider Monkey)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Oct-10-25 09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Sep-17-25 05:11AM	Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 (GlobeNewswire)
Sep-09-25 09:01AM	Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-22-25 06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 12:13AM	LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT (Insider Monkey) -13.03%
Aug-19-25 04:01PM	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) (GlobeNewswire)
Aug-07-25 05:55PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:50PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-25 05:31PM	KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 \| DelveInsight (PR Newswire)
Jul-25-25 08:13AM	scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 01:01AM	CLDX- A Promising Biotech Name Targeting CSU (MoneyShow) +6.18%
Jun-14-25 10:48AM	Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 (GlobeNewswire)
Jun-12-25 06:01PM	Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-10-25 04:01PM	Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress (GlobeNewswire)
Jun-06-25 08:01AM	Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors (GlobeNewswire) +9.32%
May-09-25 10:34AM	Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey) -6.10%
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:14PM	Celldex: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-25 04:01PM	Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease (GlobeNewswire) -9.31%
Apr-22-25 07:40AM	Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (Seeking Alpha)
Mar-24-25 03:24PM	Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? (Zacks) +5.80%
Mar-20-25 11:44AM	Celldex a new overweight at Morgan Stanley on urticaria candidate (SeekingAlpha)
Mar-04-25 08:01AM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-03-25 08:01AM	Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 (GlobeNewswire) -5.93%
Mar-01-25 12:45PM	Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 (GlobeNewswire)
Feb-27-25 05:30PM	Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:32PM	Celldex: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Dec-19-24 08:01AM	Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis (GlobeNewswire)
Nov-20-24 08:01AM	Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases (GlobeNewswire) +5.68%
Nov-11-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 05:30PM	Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.65%
04:25PM	Celldex: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 12:05PM	Celldex selloff creates buying opportunity, says Guggenheim (TipRanks)
Oct-26-24 05:43PM	Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire)
Oct-25-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 (GlobeNewswire)
Oct-23-24 08:39AM	Celldex Therapeutics (CLDX): A Top Small-Cap Growth Stock with Promising Clinical Results (Insider Monkey)
Oct-15-24 06:10PM	Celldex Therapeutics, Inc. (CLDX): Hedge Funds Hidden Gem in Small-Cap Stocks (Insider Monkey)
Sep-25-24 10:45AM	Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 (GlobeNewswire) -12.06%
Sep-16-24 08:01AM	Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 (GlobeNewswire)
Sep-14-24 05:18PM	Celldex Therapeutics, Inc. (CLDX): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-12-24 04:01PM	Celldex Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.77%
Aug-08-24 05:25PM	Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Celldex: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:01PM	Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria (GlobeNewswire) -5.77% -8.45%
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 08:01AM	Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria (GlobeNewswire)
Jun-11-24 07:00PM	Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ... (GuruFocus.com)

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

FounderMr. Anthony S. Marucci M.B.A.

FounderDr. Tibor Keler Ph.D.

Senior VPMr. Sam Martin CPA

Chief Product Development Officer & Senior VPMs. Elizabeth Crowley

Senior Vice President of Regulatory AffairsDr. Margo Heath-Chiozzi M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Martin Samuel Bates	SVP AND CFO	Jan 02 '26	Option Exercise	10.38	4,817	50,000	32,942	Jan 06 04:23 PM
PEPIN RONALD	SR. VP & CBO	Dec 15 '25	Option Exercise	5.47	19,333	105,714	20,097	Dec 17 04:06 PM
Jimenez Freddy A.	SVP & GENERAL COUNSEL	Dec 04 '25	Sale	29.09	4,166	121,210	30,796	Dec 08 04:20 PM
FREDDY A JIMENEZ	Officer	Dec 04 '25	Proposed Sale	29.10	4,166	121,210		Dec 04 04:04 PM
Wright Richard M.	Former Officer	Nov 13 '25	Option Exercise	14.06	49,298	692,913	70,131	Nov 17 04:17 PM
Wright Richard M.	Former Officer	Nov 13 '25	Sale	24.00	49,298	1,183,177	20,833	Nov 17 04:17 PM
RICHARD M WRIGHT	Officer	Nov 13 '25	Proposed Sale	24.00	49,298	1,183,177		Nov 13 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDX

Celldex Therapeutics Inc

Upgrade your Finviz experience